[Ip-health] KEI comments to the Senate Finance Committee Report on the Price of Sovalid

Jamie Love james.love at keionline.org
Sat Mar 5 07:10:36 PST 2016


I have to fix some stupid typos in the blog, so probably better and less
confusing to read from the web page.

http://keionline.org/node/2438

On Sat, Mar 5, 2016 at 10:04 AM, Jamie Love <james.love at keionline.org>
wrote:

> * Provides an answer to: What is the appropriate price for a drug
> protected by a patent or another exclusive right?
>
> Source URL: http://keionline.org/node/2438
>
> KEI comments to the Senate Finance Committee Report on the Price of Sovalid
>
> 5. March 2016 - 8:34
>
> On March 4, 2016, KEI provided comments to the US Senate Committee on
> Finance on a report prepared by staff for Senators Grassley and Wyden that
> was issued by the committee on December 2015, titled The Price of Sovaldi
> and Its Impact on the U.S. Health Care System.” Senators Grassley and Wyden
> asked the public to comment on various issues raised in the report. The
> comments we filed on March 4 including three major sections.
>
> The first provided an answer to the following question: What is the
> appropriate price for a drug protected by a patent or another exclusive
> right? The comments on drug pricing elaborated on an earlier paper in Plos
> [2], and presented a model for drug pricing that was designed to eliminate
> price based formulates for products, expand access, and optimize R&D
> objectives, including innovation for patients with rare diseases, within
> budget constraints. This is a short and fairly accessible version of the
> work in progress at KEI on a more detailed and empirically based model of
> drug pricing, and fills in some of the gaps KEI sees as missing in the
> current drug pricing discussions.  Novel for the US debate of drug
> pricing are the use of rebates with outlays exceed budget targets.
>
> The second topic as a short discussion of the KEI/UACT petition to the
> Army and the NIH to use the government's royalty free or march-in rights on
> the patents on the prostate cancer drug Xtandi.
>
> The third issue mentioned was the 2015 proposal by Senator Sanders to
> create a special system of government use of patented drugs for veterans
> health care, where compensation to patent holders is contained by the
> Department of Veterans Affairs budget for providing medicine, effectively
> putting the monopoly rather than the veterans at risk when disputes rise
> over the affordability of drugs.
>
> We also tried to point the Senate Finance Committee in the direction of
> de-linkage alternatives, but only by making brief references, including to
> some of the work of the UN Secretary General's High Level Panel on Access
> to Medicine.
>
> We had about nine important deadlines this week, and if we had more time,
> we would have made a more detailed submission to the Senate in response to
> the important questions in the report.
>
>
> [2]
> http://blogs.plos.org/yoursay/2015/10/19/talking-drug-prices-pt-4-drug-pricing-is-out-of-control-what-should-be-done-by-james-love/
> [3]
> http://keionline.org/sites/default/files/KEI-comments-sovaldi-senate-report-4march2016.pdf
>
> --
> James Love.  Knowledge Ecology International
> http://www.keionline.org/donate.html
> KEI DC tel: +1.202.332.2670, US Mobile: +1.202.361.3040, Geneva Mobile:
> +41.76.413.6584, twitter.com/jamie_love
>



-- 
James Love.  Knowledge Ecology International
http://www.keionline.org/donate.html
KEI DC tel: +1.202.332.2670, US Mobile: +1.202.361.3040, Geneva Mobile:
+41.76.413.6584, twitter.com/jamie_love



More information about the Ip-health mailing list